Clinical trials: Chimeric Antigen Receptor T-cell Therapy, open to volunteers
Chimeric Antigen Receptor T-cell Therapy, Hematologic Malignancy
Symptom Monitoring and Management Intervention After CAR-T
The goal of this study is to refine and test a digital intervention named WAYPOINT to help patients monitor and manage symptoms after CAR-T therapy.
- Trial name
- APPROACH (NCT07886190)
- Testing
- WAYPOINT
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Massachusetts General Hospital
Septic Shock, Acute Respiratory Distress Syndrome
CytOSorb TreatMent Of Critically Ill PatientS Registry
Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based…
- Conditions
- Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis
- Trial name
- COSMOS (NCT05146336)
- Testing
- CytoSorb
- Where
- 28 sites in Austria, Germany and 4 more
- Volunteers
- 3,000 people
- Sponsor
- CytoSorbents, Inc
Chimeric Antigen Receptor T-cell Therapy, B Cell Acute Lymphoblastic Leukemia (B-ALL)
Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell Lymphoma
B cell (CD19) targeted chimeric antigen receptor modified T Cells (CAR-T) has transformed treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) or B-cell lymphoma (BCL).
- Conditions
- Chimeric Antigen Receptor T-cell Therapy, B Cell Acute Lymphoblastic Leukemia (B-ALL), B Cell Lymphoma, Antibiotic Prophylaxis
- Trial name
- PREV-CART (NCT07754682)
- Testing
- Immunoglobulin, antibiotic prophylaxis
- Volunteers
- 228 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cytokine Release Syndrome, Neoplasms
Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event
Background: Drugs or cell therapies to treat cancer can sometimes cause cytokine release syndrome (CRS). That is, the body makes too many cytokines after treatment. Cytokines are proteins that play a role in the immune system.
- Conditions
- Cytokine Release Syndrome, Neoplasms, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Trial name
- NCT07499128
- Testing
- TempTraq, VitalTraq
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- National Cancer Institute (NCI)
Fatigue Symptom, Lymphoma Non-Hodgkin
Study of the Association Between Fatigue Experienced by Patients and the Specific Side Effects of CART Cells, During the First Month After Administration for Non-Hodgkin's Lymphoma
The incidence of cancer in 2023 is estimated at 433136 cases, according to INCa. Haemopathies account for 12% of these new cases of cancer cases of cancer, and around two-thirds are lymphoid haemopathies, in particular lymphomas.
- Conditions
- Fatigue Symptom, Lymphoma Non-Hodgkin, Chimeric Antigen Receptor T-cell Therapy, Adverse Events
- Trial name
- CAR-TIGUE (NCT06890091)
- Testing
- Fatigue assessment
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris